Mga Batayang Estadistika
| LEI | 54930045CGQ3XUO9T533 |
| CIK | 926617 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aspira Women's Health Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employe |
|
| September 3, 2025 |
STATEMENT OF WORK ASPIRA WOMEN’S HEALTH, INC. AND HUNGERFORD CONSULTING LLC Exhibit 10.2 STATEMENT OF WORK BETWEEN ASPIRA WOMEN’S HEALTH, INC. AND HUNGERFORD CONSULTING LLC This Statement of Work (“SOW”) is entered into as of September 2, 2025 (the “Effective Date”) and is issued in accordance with the Master Services Agreement Number ASP0001 by and between Hungerford Consulting LLC d/b/a H4D Consulting (“Consultant”) and Aspira Women’s Health, Inc. (“Client”). The partie |
|
| September 3, 2025 |
Exhibit 10.1 MASTER SERVICES AGREEMENT MASTER SERVICES AGREEMENT Number ASP0001 (this “Agreement”) is dated to be effective as of September 2, 2025, (the “Effective Date”), by and between Hungerford Consulting LLC d/b/a H4D Consulting (hereinafter “Consultant”), having its principal office at [REDACTED] and Aspira Women’s Health, Inc (hereinafter “Client,” each a “Party” and, together with Consult |
|
| August 13, 2025 |
Aspira Announces Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Aspira Announces Second Quarter 2025 Financial Results and Provides Business Update AUSTIN, Texas, August 12, 2025 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (OTCQB: AWHL), an AI enhanced bio-analytics based women’s health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operatio |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34810 Aspira Wom |
|
| July 15, 2025 |
Aspira Women’s Health Announces Appointment of Jane Pine Wood to the Board of Directors Exhibit 99.1 Aspira Women’s Health Announces Appointment of Jane Pine Wood to the Board of Directors AUSTIN, Texas, July 15, 2025 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (QTCQB: AWHL), an AI enhanced bio-analytical based women’s health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announce |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer of |
|
| June 11, 2025 |
Aspira Women’s Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women’s Health Exhibit 99.1 Aspira Women’s Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women’s Health AUSTIN, TX and WASHINGTON, D.C. — June 11th, 2025 — Aspira Women’s Health Inc., (“Aspira”) (OTCQB:AWHL), an AI enhanced bio-analytics based women’s health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announces an update |
|
| June 9, 2025 |
As filed with the Securities and Exchange Commission on June 9, 2025 As filed with the Securities and Exchange Commission on June 9, 2025 Registration No. |
|
| June 9, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aspira Women's Health, Inc. |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer of |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer of |
|
| May 19, 2025 |
Aspira Announces First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Aspira Announces First Quarter 2025 Financial Results and Provides Business Update AUSTIN, Texas, May 19, 2025 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (OTCQB: AWHL), an AI enhanced bio-analytics based women’s health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations f |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34810 Aspira Wo |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-34810 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ |
|
| May 7, 2025 |
The date of this prospectus is May 7, 2025 TABLE OF CONTENTS PROSPECTUS Filed Pursuant to 424(b)(3) Registration Statement No. 333-286561 354,988 Shares of Common Stock Up to 42,328,042 of Common Stock Aspira Women’s Health Inc. This prospectus relates to the resale from time to time of (i) 354,988 shares of common stock, par value $0.001 per share, of Aspira Women’s Health Inc. (the “Common Stock”) and (ii) up 42,328,042 of shares of Common Stock, by Trito |
|
| May 6, 2025 |
ASPIRA WOMEN’S HEALTH INC. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas 78738 ASPIRA WOMEN’S HEALTH INC. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas 78738 May 6, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: Aspira Women’s Health Inc. Registration Statement on Form S-1 Filed May 6, 2025 File No. 333-286561 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules a |
|
| May 6, 2025 |
ASPIRA WOMEN’S HEALTH INC. 12117 Bee Caves Road, Building III, Suite 100 Austin, TX 78738 ASPIRA WOMEN’S HEALTH INC. 12117 Bee Caves Road, Building III, Suite 100 Austin, TX 78738 May 6, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Joshua Gorsky Joe McCann Re: Aspira Women’s Health Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed April 30, 2025 File No. 333-286561 Dear Ladies and Gentlemen: This letter |
|
| May 6, 2025 |
As filed with the Securities and Exchange Commission on May 6, 2025 As filed with the Securities and Exchange Commission on May 6, 2025 Registration Statement No. |
|
| May 1, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Aspira Women’s Health Inc. |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on April 30, 2025 As filed with the Securities and Exchange Commission on April 30, 2025 Registration Statement No. |
|
| April 30, 2025 |
ASPIRA WOMEN’S HEALTH INC. 12117 Bee Caves Road, Building III, Suite 100 Austin, TX 78738 ASPIRA WOMEN’S HEALTH INC. 12117 Bee Caves Road, Building III, Suite 100 Austin, TX 78738 April 30, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Joshua Gorsky Joe McCann Re: Aspira Women’s Health Inc. Registration Statement on Form S-1 Filed April 16, 2025 File No. 333-286561 Dear Ladies and Gentlemen: This letter sets forth resp |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commissi |
|
| April 16, 2025 |
As filed with the Securities and Exchange Commission on April 15, 2025 As filed with the Securities and Exchange Commission on April 15, 2025 Registration Statement No. |
|
| April 16, 2025 |
Aspira Women’s Health Inc. Announces Receipt of Delisting Notification from Nasdaq Exhibit 99.1 Aspira Women’s Health Inc. Announces Receipt of Delisting Notification from Nasdaq April 16, 2025 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that on April 15, 2025, the Company received written notice (the “Noti |
|
| April 16, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Aspira Women’s Health Inc. |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 8, 2025 |
Exhibit 99.1 Aspira Appoints Three New Directors, Executes $2.0 Million Equity Purchase Agreement New Directors Bring Extensive Commercial Healthcare Relationships to Expand Business Development Opportunities. April 8, 2025 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 8, 2025 |
Exhibit 10.1 EQUITY PURCHASE AGREEMENT This Equity Purchase Agreement is entered into effective as of this 4th day of April, 2025 (this “Agreement”), by and between ASPIRA WOMEN’S HEALTH INC., a Delaware company (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (the “Investor”). WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the |
|
| March 31, 2025 |
Amendment to Amended and Restated Bylaws of Aspira Women’s Health Inc. Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF ASPIRA WOMEN’S HEALTH INC. (the “Corporation”) Section 2.6 of Article II of the Amended and Restated Bylaws of the Corporation (the “Bylaws”), is hereby amended and restated in its entirety as follows: “The holders of stock representing one-third (33.33%) of the voting power of all shares of stock issued and outstanding and entitled to vo |
|
| March 31, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and Michael Buhle (“Executive,” and together with the Company, the “Parties”) is effective as of the first signature of this document (the “Effective Date”). WHEREAS, the Company and Executive desire to enter into a Employment Agreement; NOW, TH |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 27, 2025 |
Exhibit 4.14 February 11, 2025 Holder of Warrants to Purchase Common Stock of Aspira Women’s Health Inc. set forth on Exhibit A attached hereto Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the Securities Purchase Agreement dated June 30, 2024 pursuant to which Aspira Women’s Health Inc. (the “Company”) sold shares of common stock and warrants (the “Existing Warrants” |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer o |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34810 Aspira Women’s Health In |
|
| March 27, 2025 |
Exhibit 10.11 SEPARATION AGREEMENT AND GENERAL RELEASE 1. This Separation Agreement and General Release (“Agreement”) is between Nicole Sandford (“Employee”) and Aspira Women’s Health Inc. (the “Company”), to resolve any and all outstanding issues between the parties, including any and all claims against the Company, its parents, subsidiaries, departments or affiliates and their predecessors, succ |
|
| March 27, 2025 |
Exhibit 99.1 Aspira Women’s Health Reports Fourth Quarter and Full Year 2024 Financial Results Record 2024 OvaSuite revenue of $9.2 million and volume of 24,305 units sold AUSTIN, Texas, Mar. 27, 2025 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic too |
|
| March 27, 2025 |
Exhibit 19.1 ASPIRA WOMEN’S HEATLH INC. INSIDER TRADING POLICY This Insider Trading Policy (this “Policy”) of Aspira Women’s Health Inc. (the “Company”) confirms procedures that all Insiders (as defined below) must follow. This Policy is effective as of March 19, 2021 and is subject to modification from time to time as the Company’s board of directors deems necessary or advisable. 1. Persons Subje |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2025 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2025 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 11, 2025 |
Aspira Women’s Health Announces Closing of $1.37 Million Private Placement of Convertible Notes Exhibit 99.1 Aspira Women’s Health Announces Closing of $1.37 Million Private Placement of Convertible Notes AUSTIN, Texas, March 11, 2025 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into a securities purc |
|
| March 11, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 5, 2025 (the “Effective Date”), between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject t |
|
| March 11, 2025 |
Exhibit 4.1 FORM OF SENIOR SECURED CONVERTIBLE PROMISSORY NOTE THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF OR UPON THE CONVERSION OF ACCRUED INTEREST AS FURTHER DESCRIBED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR |
|
| March 11, 2025 |
Exhibit 4.2 FORM OF WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer of |
|
| February 14, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employe |
|
| February 13, 2025 |
ASPIRA WOMEN’S HEALTH INC. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas 78738 ASPIRA WOMEN’S HEALTH INC. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas 78738 February 13, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Aspira Women’s Health Inc. File No. 333-284182 Application for Withdrawal on Form RW pursuant to Rule 477 of the Securities Act of 1933 of the Registration Statement on Form S-1 |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration Statement No. |
|
| February 11, 2025 |
Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between Aspira Women’s Health Inc. and ThinkEquity LLC as Representative of the Several Underwriters UNDERWRITING AGREEMENT between Aspira Women’s Health Inc. and ThinkEquity LLC as Representative of the Several Underwriters New York, New York [·], 2025 ThinkEquity LLC as Representative of the several Underwriters named on Schedule 1 hereto 17 State Street, 22nd |
|
| February 11, 2025 |
Exhibit 4.11 PRE-FUNDED COMMON SHARES PURCHASE WARRANT aspira women’s health INC. Warrant Shares: [] Initial Exercise Date: [●], 2025 THIS PRE-FUNDED COMMON SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| February 11, 2025 |
Exhibit 4.12 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT made as of February , 2025 (the “Issuance Date”), between Aspira Women’s Health Inc., a Delaware corporation, with offices at 12117 Bee Caves Road, Building III, Suite 100, Austin, Texas 78738 (“Company”), and Broadridge Corporate Issuer Solutions, LLC, with offices at 51 Mercedes Way, Edgewood, NY 11717 (the “Warrant Agent”). WHEREAS, |
|
| February 11, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ASPIRA WOMEN’S HEALTH INC. |
|
| February 11, 2025 |
Exhibit 4.13 FORM OF CERTIFICATED WARRANT WARRANT TO PURCHASE COMMON STOCK ASPIRA WOMEN’S HEALTH INC. Warrant Shares: Initial Exercise Date: , 2025 Issue Date: , 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| February 11, 2025 |
Form of Representative’s Warrant Exhibit 4.10 Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIG |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 31, 2025 |
As filed with the Securities and Exchange Commission on January 31, 2025 As filed with the Securities and Exchange Commission on January 31, 2025 Registration Statement No. |
|
| January 31, 2025 | ||
| January 31, 2025 |
EX-FILING FEES 3 ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ASPIRA WOMEN’S HEALTH INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(1)(3) |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 13, 2025 |
Slide Deck Presented by Aspira Women’s Health Inc. On January 13, 2025 Exhibit 99.1 |
|
| January 8, 2025 |
As filed with the Securities and Exchange Commission on January 8, 2025 As filed with the Securities and Exchange Commission on January 8, 2025 Registration Statement No. |
|
| January 8, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ASPIRA WOMEN’S HEALTH INC. |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 31, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 16, 2024 |
Exhibit 99.1 Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as Interim CEO CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition AUSTIN, Texas, December 16, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the de |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34810 Aspir |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-34810 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SA |
|
| November 14, 2024 |
Exhibit 99.1 Aspira Women’s Health Reports Selected Third Quarter 2024 Financial Results Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AU |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2024 |
AWH / Aspira Women's Health Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-awh093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aspira Women’s Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04537Y208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check th |
|
| October 29, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 29, 2024 |
Slide Deck Presented by Aspira Women’s Health Inc. on October 29, 2024 Exhibit 99.1 |
|
| October 24, 2024 |
Exhibit 99.1 www.aspirawh.com October 24, 2024 Dear Shareholder, Yesterday, it was my honor to share news of an exciting development that we believe will shape Aspira Women’s Health for many years to come. We have been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health, an initiative to address critical unmet challenges in women’s h |
|
| October 24, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 23, 2024 |
Exhibit 99.1 Aspira Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis AUSTIN, Texas – Oct. 23, 2024 – Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic |
|
| October 23, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 18, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer |
|
| September 13, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 09, 2024 Aspira Women's Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 13, 2024 |
Slide Deck Presented by Aspira Women's Health Inc. on September 9, 2024 Exhibit 99.1 |
|
| September 5, 2024 |
Up to 2,566,667 Shares of Common Stock Aspira Women’s Health Inc. PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-281745 Up to 2,566,667 Shares of Common Stock Aspira Women’s Health Inc. Pursuant to this prospectus, the selling stockholder identified herein (the “Selling Stockholder”) is offering on a resale basis up to an aggregate of 2,566,667 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of Aspira |
|
| August 29, 2024 |
Aspira Women’s Health, Inc. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas Aspira Women’s Health, Inc. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas August 29, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Aspira Women’s Health, Inc. Registration Statement on Form S-3 Filed August 23, 2024 File No. 333-281745 Ladies and Gentlemen: Pursuant to Rule 461 of the General |
|
| August 23, 2024 |
As filed with the Securities and Exchange Commission on August 23, 2024 As filed with the Securities and Exchange Commission on August 23, 2024 Registration No. |
|
| August 23, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) ASPIRA WOMEN’S HEALTH INC. |
|
| August 20, 2024 |
Calculation of Filing Fee Tables Form S-8 (Form Type) Aspira Women’s Health Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity(1) Common Stock, $0.001 par valu |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 As filed with the Securities and Exchange Commission on August 20, 2024 Registration No. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34810 Aspira Wom |
|
| August 13, 2024 |
Exhibit 10.3 SECOND AMENDMENT OF EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT OF EMPLOYMENT AGREEMENT (this “Second Amendment”) between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and Nicole Sandford (“Executive,” and together with the Company, the “Parties”) is effective as of September 1, 2024 (the “Second Amended Restated Effective Date”). WHEREAS, the Company and Executiv |
|
| August 13, 2024 |
Exhibit 10.4 AMENDMENT OF EMPLOYMENT AGREEMENT THIS AMENDMENT OF EMPLOYMENT AGREEMENT between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and Sandra Milligan (“Executive,” and together with the Company, the “Parties”) is effective as of September 1, 2024 WHEREAS the Company and Executive entered into an Employment Agreement on March 16, 2024 (“Employment Agreement”) and WHE |
|
| August 13, 2024 |
Exhibit 10.5 CONSULTING AGREEMENT Effective as of August 15, 2024 (the “Effective Date”), Aspira Women’s Health Inc. (the “Company”), and John Kallassy (“Consultant”) agree as follows: 1. Services and Compensation. (a) Services. Consultant agrees to provide the services described in Exhibit A attached hereto (the “Services”). The consulting relationship between the Company and Consultant, whether |
|
| August 12, 2024 |
Aspira Women’s Health Reports Second Quarter 2024 Financial Results Q2 2024 OvaSuiteSM revenue of $2. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Aspira Women's Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 2, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-278867 Prospectus Supplement (To prospectus dated April 25, 2024) $4,450,000 Common Stock We have entered into an At The Market Offering Agreement (the “Offering Agreement”), dated August 2, 2024, with H.C. Wainwright & Co., LLC (the “Sales Agent” or “Wainwright”), as sales agent relating to the sale of our shares of our common stock, par value |
|
| August 2, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2024 Aspira Women's Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 2, 2024 |
AT THE MARKET OFFERING AGREEMENT August 2, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Aspira Women’s Health Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreeme |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 Aspira Women's Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 31, 2024 |
Form of Warrant Inducement Agreement Exhibit 10.1 ASPIRA WOMEN’S HEALTH INC. 12117 Bee Caves Road, Building III, Suite 100 Austin, TX 78738 July 31, 2024 To the Holders of Common Stock Purchase Warrants of Aspira Women’s Health Inc. Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: Aspira Women’s Health Inc. (the “Company”) is pleased to offer (this “Offer”) to you (“Holder”, “you” or similar termi |
|
| July 31, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 31, 2024 |
590 Madison Avenue, 36th Floor, New York, NY 10022, 212-624-20601 Member FINRA, SIPC Exhibit 99.1 July 31, 2024 CONFIDENTIAL Aspira Women’s Health Inc. Attention: Nicole Sandford 12117 Bee Caves Road, Building III Suite 100 Austin, TX 78738 The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by Aspira Women’s Health Inc. (the “Company”) to render Financial Services (as defined below) to the |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employe |
|
| July 29, 2024 |
Aspira Women’s Health Appoints Mr. John Ragard to its Board of Directors Mr. Ragard further strengthens the Board bringing more than 46 years of significant public equity investment and Wall Street experience AUSTIN, Texas – July 29, 2024 – Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic |
|
| July 25, 2024 |
2,497,054 Shares of Common Stock Aspira Women’s Health Inc. PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-280848 2,497,054 Shares of Common Stock Aspira Women’s Health Inc. Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of 2,497,054 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of Aspira Women’s H |
|
| July 23, 2024 |
Aspira Women’s Health, Inc. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas Aspira Women’s Health, Inc. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas July 23, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Aspira Women’s Health, Inc. Registration Statement on Form S-3 Filed July 17, 2024 File No. 333-280848 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rul |
|
| July 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) ASPIRA WOMEN’S HEALTH INC. |
|
| July 17, 2024 |
As filed with the Securities and Exchange Commission on July 17, 2024 As filed with the Securities and Exchange Commission on July 17, 2024 Registration No. |
|
| July 11, 2024 |
AWH / Aspira Women's Health Inc. / SCHULER JACK W Activist Investment SC 13D/A 1 awh13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 16)* Aspira Women's Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04537Y208 (Cusip Number) Jack W. Schuler PO Box 531 Lake Bluff IL 60044 (520) 906-2991 (Name, Address, and Telephone |
|
| July 5, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 01, 2024 Aspira Women's Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 2, 2024 |
Aspira Women’s Health Announces $1.935 Million Private Placement Equity Financing Exhibit 99.1 Aspira Women’s Health Announces $1.935 Million Private Placement Equity Financing AUSTIN, Texas, July 1, 2024 (GLOBE NEWSWIRE) - Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated |
|
| July 2, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 2, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 30, 2024 (the “Effective Date”), between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject t |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2024 Aspira Women's Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employe |
|
| June 27, 2024 |
SECOND AMENDMENT Employment Agreement EX.10.1 SECOND AMENDMENT TO Employment Agreement This SECOND AMENDMENT (the “Second Amendment”), dated as of June 5, 2024, (the “Second Amendment Date”) to the Employment Agreement (the “Employment Agreement”), dated May 16, 2023 (“Effective Date”), is made by and among Dr. Torsten Hombeck (“Executive”) and Aspira Women’s Health Inc. and is effective as of June 1, 2024, for itself and on behalf of |
|
| June 18, 2024 |
AWH / Aspira Women's Health Inc. / SCHULER JACK W Activist Investment SC 13D/A 1 awh13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 15)* Aspira Women's Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04537Y208 (Cusip Number) Jack W. Schuler PO Box 531 Lake Bluff IL 60044 (520) 906-2991 (Name, Address, and Telephone |
|
| June 14, 2024 |
Aspira Women’s Health Provides Commercial, Reimbursement and Cash Guidance Updates Monthly OvaSuiteTM product volume grew by more than 26% in May compared to January Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite Cash used in operations guidance for 2024 expected to be lowered AUSTIN, Texas, Jun 12, 2024 (GLOBE NEWSWIRE) - Aspira Women’s Health Inc. |
|
| June 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employe |
|
| June 7, 2024 |
EX.10.1 SECOND AMENDMENT TO Employment Agreement This SECOND AMENDMENT (the “Second Amendment”), dated as of June 5, 2024, (the “Second Amendment Date”) to the Employment Agreement (the “Employment Agreement”), dated May 16, 2023 (“Effective Date”), is made by and among Dr. Torsten Hombeck (“Executive”) and Aspira Women’s Health Inc. and is effective as of June 1, 2024, for itself and on behalf of |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer |
|
| May 15, 2024 |
Aspira Women’s Health Reports First Quarter 2024 Financial Results Q1 2024 OvaSuiteSM revenue of $2. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34810 Aspira Wo |
|
| May 14, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 ASPIRA WOMEN’S HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commissi |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employ |
|
| April 26, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-278867 PROSPECTUS SUPPLEMENT (To Prospectus dated April 25, 2024) $3,200,000 of Common Stock This prospectus supplement and the accompanying prospectus relate to the issuance and sale of up to $3,200,000 of shares of our common stock, par value $0.001 per share, or the Registered Purchase Shares, that we may sell to Lincoln Pa |
|
| April 24, 2024 |
Aspira Women’s Health Inc. 12117 Bee Caves Road, Building III, Suite 100 Austin, TX 78738 (512) 519-0400 April 24, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika Sheppard Re: Aspira Women’s Health Inc. Registration Statement on Form S-3 File No. 333-278867 Acceleration Request Requested Date |
|
| April 22, 2024 |
Exhibit 4.8 ASPIRA WOMEN’S HEALTH INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2.03 |
|
| April 22, 2024 |
As filed with the Securities and Exchange Commission on April 22, 2024 As filed with the Securities and Exchange Commission on April 22, 2024 Registration No. |
|
| April 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Aspira Women’s Health Inc. |
|
| April 11, 2024 |
Up to 1,571,000 shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-278543 PROSPECTUS Up to 1,571,000 shares of Common Stock This prospectus covers the offer and resale by the selling stockholders identified in this prospectus of up to an aggregate of 1,571,000 shares of our common stock issuable upon the exercise of outstanding common warrants that were issued to the selling stockholders on J |
|
| April 10, 2024 |
Aspira Women’s Health Inc. 12117 Bee Caves Road, Building III, Suite 100 Austin, TX 78738 (512) 519-0400 April 10, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Aspira Women’s Health Inc. Registration Statement on Form S-1 File No. 333-278543 Acceleration Request Requested Date: Thu |
|
| April 8, 2024 |
AWH / Aspira Women's Health Inc. / Schultz Eric Adam - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (c), AND (d) (Amendment No. 1) Aspira Women’s Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04537Y109 (CUSIP Number) January 14, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| April 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aspira Women’s Health Inc. |
|
| April 5, 2024 |
As filed with the Securities and Exchange Commission on April 5, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 5, 2024 Registration No. |
|
| April 1, 2024 |
Exhibit 97.1 Aspira Women’s Health Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Aspira Women’s Health Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment o |
|
| April 1, 2024 |
Exhibit 10.18 AMENDMENT NO. 5 TO TESTING AND SERVICES AGREEMENT This AMENDMENT NO. 5 TO TESTING AND SERVICES AGREEMENT (this “Amendment”) is made and entered into as of December 6, 2022 (“Amendment Effective Date”), by and between Quest Diagnostics Incorporated, a Delaware corporation (“Quest Diagnostics”) on the one hand, and Aspira Women’s Health Inc. (f/k/a Vermillion, Inc.), a Delaware cor |
|
| April 1, 2024 |
Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Introduction Aspira Women’s Health Inc. (the “Company,” “we,” “us” or “our”) has one security registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, which is our common stock. Our common stock is listed on The Nasdaq Capital Market under the |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Def |
|
| April 1, 2024 |
Exhibit 10.28 EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement, effective as of March 1st 2023 (“Effective Date”), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having a principal place of business at 450 Brookline Ave., Boston, MA 02215 (“DFCI”) and Aspira Women’s Health Inc., a corporation having a principal place of business at 35 Nutme |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K T Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34810 Aspira Women’s Health In |
|
| March 28, 2024 |
Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results 2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast sche |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employ |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commissi |
|
| March 25, 2024 |
EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO Employment Agreement This FIRST AMENDMENT (the “Amendment”), dated as of March 20, 2024 (“Amendment Date”), to the Employment Agreement (the “Employment Agreement”), dated May16, 2023 (“Effective Date”), is made by and among Torsten Hombeck (“Executive”) and Aspira Women’s Health Inc., for itself and on behalf of its wholly owned affiliates (collectively “As |
|
| March 21, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and Sandra Milligan (“Executive,” and together with the Company, the “Parties”) is effective as of Executive’s first day of employment (the “Effective Date”). WHEREAS, the Company and Executive desire to enter into a Employment Agreement; NOW, T |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employ |
|
| January 26, 2024 |
Form of Warrant Amendment to Common Stock Purchase Warrant Exhibit 4.3 AMENDMENT TO COMMON STOCK PURCHASE WARRANTS This AMENDMENT TO COMMON STOCK PURCHASE WARRANTS (this “Amendment”) is entered into as of January 26, 2024, by and between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and [•] (the “Holder”). WHEREAS, the Holder is the holder of a Common Stock Purchase Warrant issued on August 24, 2022 (the “August 2022 Warrant”) to pur |
|
| January 26, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT January 24, 2024 Aspira Women’s Health Inc. 12117 Bee Caves Road, Building III, Ste 100 Austin, Texas 78738 Attn: Chief Financial Officer Dear Dr. Torsten Hombeck: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Aspira Women’s Health Inc., a Delaware corporation (the “Company”), that |
|
| January 26, 2024 |
1,371,000 Shares of Common Stock Pre-Funded Warrants to Purchase 200,000 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-252267 PROSPECTUS SUPPLEMENT (To Prospectus dated January 28, 2021) 1,371,000 Shares of Common Stock Pre-Funded Warrants to Purchase 200,000 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering in a registered direct offering to certain purchasers (i) 1,371,000 shares o |
|
| January 26, 2024 |
Form of Pre-Funded Warrant 2024 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ASPIRA WOMEN’S HEALTH INC. Warrant Shares: Issue Date: January [•], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| January 26, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 24, 2024, between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| January 26, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 26, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Aspira Women’s Health Inc. |
|
| January 26, 2024 |
As filed with the Securities and Exchange Commission on January 26, 2024 As filed with the Securities and Exchange Commission on January 26, 2024 Registration No. |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Data of earliest event reported): January 24, 2024 ASPIRA WOMEN’S HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Comm |
|
| January 25, 2024 |
Form of Warrant Amendment to Common Stock Purchase Warrant Exhibit 4.3 AMENDMENT TO COMMON STOCK PURCHASE WARRANTS This AMENDMENT TO COMMON STOCK PURCHASE WARRANTS (this “Amendment”) is entered into as of January 26, 2024, by and between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and [•] (the “Holder”). WHEREAS, the Holder is the holder of a Common Stock Purchase Warrant issued on August 24, 2022 (the “August 2022 Warrant”) to pur |
|
| January 25, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT January 24, 2024 Aspira Women’s Health Inc. 12117 Bee Caves Road, Building III, Ste 100 Austin, Texas 78738 Attn: Chief Financial Officer Dear Dr. Torsten Hombeck: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Aspira Women’s Health Inc., a Delaware corporation (the “Company”), that |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Data of earliest event reported): January 24, 2024 ASPIRA WOMEN’S HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commis |
|
| January 25, 2024 |
Form of Warrant to Purchase Common Stock Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 25, 2024 |
Form of Pre-Funded Warrant to Purchase Common Stock Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ASPIRA WOMEN’S HEALTH INC. Warrant Shares: Issue Date: January [•], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| January 25, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 24, 2024, between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Emplo |
|
| January 5, 2024 |
Slide Deck Presented by Aspira Women’s Health Inc. On January 4, 2024 Exhibit 99.1 |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employe |
|
| December 26, 2023 |
AWH / Aspira Women's Health Inc. / Schultz Eric Adam - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (c), AND (d) Aspira Women’s Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04537Y109 (CUSIP Number) December 14, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| December 6, 2023 |
Exhibit 99.1 Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis Data supports EndoCheckTM to be the first blood test for the identification of localized endometriosis, including endometrioma Platform migration to begin on the Company’s EndoMDxTM test for broader endometriosis indications AUSTIN, Texas – December 6, 2023 – Aspira Women’s |
|
| December 6, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Empl |
|
| November 13, 2023 |
Exhibit 99.1 Aspira Women’s Health Reports Third Quarter 2023 Financial Results Product revenue increased 9% to $2.2 million for the quarter, and 19% to $7.0 million year to date OvaSuite sales volume increased 5% to 5,783 units for the quarter, and 16% to 18,331 units year to date Third quarter cash utilization of $3.3 million, a decrease of 56% compared to third quarter last year Confer |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34810 Aspir |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Emp |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K/A (Amendment No. 1) T Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34810 Aspi |
|
| October 23, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Empl |
|
| October 23, 2023 |
Aspira Women’s Health Establishes a New Clinical Advisory Board Exhibit 99.1 Aspira Women’s Health Establishes a New Clinical Advisory Board Clinical Advisory Board comprised of preeminent physicians with deep clinical expertise in gynecologic health AUSTIN, Texas – October 23, 2023 – Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic t |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commi |
|
| September 13, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Em |
|
| September 12, 2023 |
Amended Consulting Agreement between Aspira Women’s Health Inc. and NuPath, LLC Exhibit 10.1 AMENDED CONSULTING AGREEMENT This FIRST AMENDMENT (“Amendment”), effective as of September 16, 2023 (“Amendment Date”), to the Consulting Agreement (this “Agreement”), dated April 22, 2022 (“Effective Date”), is made by and among NuPath LLC and Ryan Phan (collectively, “NuPath”) and Aspira Women’s Health Inc., for itself and on behalf of its wholly owned affiliates (collectively “As |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Comm |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34810 Aspira Wom |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commis |
|
| August 14, 2023 |
Exhibit 99.1 Aspira Women’s Health® Reports Second Quarter 2023 Financial Results Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022. OvaSuite volume of 6,289 units, an increase of 16% year-over-year Achieved cash used in operations of $3.4 million, a decrease of 46% compared to the second quarter of 2022 Conference Call and Web |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Comm |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employ |
|
| July 26, 2023 |
US04537Y2081 / ASPIRA WOMEN'S HEALTH INC / SCHULER JACK W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| July 24, 2023 |
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-252267 PROSPECTUS SUPPLEMENT (To Prospectus dated January 28, 2021) 1,694,820 Shares Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering in a registered direct offering to certain purchasers, 1,650,473 shares of our common stock, par value $0.001 per share, at an offering |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 ASPIRA WOMEN’S HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commissio |
|
| July 24, 2023 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 20, 2023, between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Data of earliest event reported): July 19, 2023 ASPIRA WOMEN’S HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commissio |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employe |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employe |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employer |
|
| May 16, 2023 |
Employment Agreement between Aspira Women’s Health Inc. and Torsten Hombeck, effective June 15, 2023 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and Torsten Hombeck (“Executive,” and together with the Company, the “Parties”) is effective as of June 15, 2023, or a date mutually agreeable to the parties (the “Effective Date”). WHEREAS, the Company and Executive desire to enter into an Empl |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34810 Aspira Wo |
|
| May 11, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ASPIRA WOMEN’S HEALTH INC. Aspira Women’s Health Inc. (the “Corporation”), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), hereby certifies as follows: 1. This Certificate of Amendment amends the p |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commissio |
|
| May 11, 2023 |
Exhibit 99.1 First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year First Quarter cash used in operations of $5.7 million, a decrease of 44% year-over-year Conference Call and Webcast scheduled for today 4:30 pm Eastern Time AUSTIN, Texas — May 11, 2023 — Aspira Women’s Health In |
|
| May 11, 2023 |
Item 9.01. Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commissio |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2023 |
Exhibit 99.1 Aspira Women’s Health Announces Preliminary First Quarter 2023 OvaSuite Volume Increase of 29% and Plans to Announce Full Earnings Results on May 11, 2023 Preliminary first quarter 2023 volume was 6,259 tests, an increase of 29% compared to last year, the highest volume quarter in the company’s history Management to host its first quarter earnings conference call on Thursday, May 11 |
|
| April 28, 2023 |
Item 9.01. Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commiss |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| March 30, 2023 |
PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of March 28, 2023, is made by and between ASPIRA WOMEN’S HEALTH INC. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commiss |
|
| March 30, 2023 |
Employment Agreement between Aspira Women’s Health Inc. and Dr. Ryan Phan, effective May 3, 2022#† EX-10.33 3 awh-20221231xex1033.htm EX-10.33 Exhibit 10.33 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and Dr. Ryan Phan, PhD. (“Executive,” and together with the Company, the “Parties”) is effective as of Executive’s first day of employment (the “Effective Date”). WHEREAS, the Company and Executive de |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K T Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34810 Aspira Women’s Health In |
|
| March 30, 2023 |
REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 28, 2023, is entered into by and between ASPIRA WOMEN’S HEALTH INC. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No . ) Filed by the R egistrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission O nly (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| March 30, 2023 |
EX-10.32 2 awh-20221231xex1032.htm EX-10.32 Exhibit 10.32 EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and Minh Merchant (“Executive,” and together with the Company, the “Parties”) is effective as of March 28, 2023 (the “Effective Date”). The terms set forth herein shall supersed |
|
| March 29, 2023 |
$10,000,000 of Common Stock 715,990 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252267 PROSPECTUS SUPPLEMENT (To Prospectus dated January 28, 2021) $10,000,000 of Common Stock 715,990 Shares of Common Stock This prospectus supplement and the accompanying prospectus relate to the issuance and sale of up to $10,000,000 of shares of our common stock, par value $0.001 per share, or the Purchase Shares, |
|
| March 22, 2023 |
Item 9.01. Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commiss |
|
| March 22, 2023 |
Exhibit 99.1 Aspira Women’s Health Reports Fourth Quarter and Full Year 2022 Financial Results 2022 total revenue of $8.2 million, an increase of 20% year-over-year 2022 total OvaSuiteSM volume of 21,423 units, an increase 23% year-over-year Fourth quarter 2022 cash utilization of $7.1 million Conference Call and Webcast scheduled for today at 4:30 pm Eastern Time AUSTIN, Texas — March 22, 2023 — |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No . ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commissi |
|
| March 3, 2023 |
Item 9.01. Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Comm |
|
| March 2, 2023 |
Item 9.01. Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commissi |
|
| March 2, 2023 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Restated Agreement”) between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and Nicole Sandford (“Executive,” and together with the Company, the “Parties”) is effective as of March 1, 2023 (the “Restated Effective Date”). WHEREAS, the Company and Executive entered i |
|
| February 15, 2023 |
AWH / Aspira Women's Health Inc / SEAMARK CAPITAL LP - SC 13G/A Passive Investment SC 13G/A 1 d376892dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (c), AND (d) (Amendment No. 4)* Aspira Women’s Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04537Y109 (CUSIP Number) December 31, 2022 (Date of Event |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 10, 2023 |
EX-1.1 Exhibit 1.1 Aspira Women’s Health Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement February 10, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Aspira Women’s Health Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as f |
|
| February 10, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252267 PROSPECTUS SUPPLEMENT (to Prospectus dated January 28, 2021) $12,500,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor, dated February 10, 2023, relating to the sale of shares of our common stock, par value $0.001 p |
|
| February 7, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ASPIRA WOMEN’S HEALTH INC. Aspira Women’s Health Inc. (the “Corporation”), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment amends the provisions of the Corpor |
|
| February 7, 2023 |
Item 9.01. Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction of incorporation) (Commi |
|
| January 10, 2023 |
Investor Slides Presented by Aspira Women’s Health Inc. on January 10, 2023 Exhibit 99.1 |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Empl |
|
| January 10, 2023 |
Investor Slides to be Presented by Aspira Women’s Health Inc. on January 10, 2023 Exhibit 99.1 |
|
| January 10, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Em |
|
| January 9, 2023 |
Exhibit 99.1 Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Achievement of Cash Utilization Guidance, and Other Highlights Preliminary fourth quarter 2022 volume was 5,643 tests, an increase of 18% compared to last year Achieved previously provided cash utilization guidance for the fourth quarter and full year Anticipate additional cost savings of ~$6 million year ov |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Emplo |
|
| December 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| December 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS E |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Emp |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Emp |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Emp |
|
| November 30, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and Marlene McLennan (“Executive,” and together with the Company, the “Parties”) is effective as of Executive’s first day of employment, which commenced December 1, 2022 (the “Effective Date”). WHEREAS, the Company and Executive desire to ente |
|
| November 10, 2022 |
Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE ? This agreement (Agreement) is entered into between Robert Beechey (Employee) and Aspira Women's Health (Company). ? 1.Termination of Employment Relationship. The employment relationship between Employee and the Company terminated on Wednesday, November 30, 2022 (Termination Date). The Company may relieve Employee of all duties and place the Employee |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34810 Aspir |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-34810 33-0595156 (State or other jurisdiction (Commission (IRS Employe |
|
| November 10, 2022 |
Exhibit 99.1 ? Aspira Women?s Health Reports Third Quarter 2022 Financial Results ? Increased year-over-year product revenue by 26% to $2.0 million and year-over-year product volume by 29% to 5,524 units ? Reconfirmed fourth quarter launch of OvaWatch ovarian cancer risk assessment and announced rebranding of the ovarian cancer product portfolio as OvaSuite ? Executed and fully funded a sponsored |
|
| November 10, 2022 |
Exhibit 10.1 FIRST AMENDMENT ? TO ? Employment Agreement ? ? This FIRST AMENDMENT (the"Amendment''), dated as of September 20, 2022 ("Amendment Date"), to the Employment Agreement (the "Employment Agreement"), dated December 14, 2017 ("Effective Date"), is made by and among Robert Beechey ("Executive") and Aspira Women's Health Inc., for itself and on behalf of its wholly owned affiliates (collect |
